ENRIQUE MARÍA OCIO SAN MIGUEL-rekin lankidetzan egindako argitalpenak (24)

2024

  1. The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression

    Blood cancer journal, Vol. 14, Núm. 1, pp. 74

2022

  1. Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 28, Núm. 21, pp. 4771-4781

  2. Recovery of polyclonal immunoglobulins during treatment in patients ineligible for autologous stem-cell transplantation is a prognostic marker of longer progression-free survival and overall survival

    British Journal of Haematology, Vol. 198, Núm. 2, pp. 278-287

2021

  1. 6q deletion in Waldenström macroglobulinaemia negatively affects time to transformation and survival

    British Journal of Haematology, Vol. 192, Núm. 5, pp. 843-852

  2. Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis

    Leukemia, Vol. 35, Núm. 1, pp. 245-249

  3. Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial

    Blood Cancer Journal, Vol. 11, Núm. 5

  4. Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development

    Blood, Vol. 138, Núm. 17, pp. 1583-1589

2020

  1. Pembrolizumab as consolidation strategy in patients with multiple myeloma: Results of the GEM-pembresid clinical trial

    Cancers, Vol. 12, Núm. 12, pp. 1-13

2019

  1. Correction: Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role (Leukemia, (2018), 32, 11, (2427-2434), 10.1038/s41375-018-0072-6)

    Leukemia

  2. Drug-induced thrombotic microangiopathy during maintenance treatment in a patient with multiple myeloma

    HemaSphere, Vol. 3, Núm. 3

  3. Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis

    Leukemia, Vol. 33, Núm. 5, pp. 1256-1267

  4. Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature

    Blood Cancer Journal, Vol. 9, Núm. 4

2018

  1. Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role

    Leukemia, Vol. 32, Núm. 11, pp. 2427-2434

2017

  1. Amiloride, an old diuretic drug, is a potential therapeutic agent for multiple myeloma

    Clinical Cancer Research, Vol. 23, Núm. 21, pp. 6602-6615

  2. Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myeloma

    Haematologica, Vol. 102, Núm. 5, pp. 922-931

2016

  1. Bence Jones proteinuria in smoldering multiple myeloma as a predictor marker of progression to symptomatic multiple myeloma

    Leukemia, Vol. 30, Núm. 10, pp. 2026-2031

  2. Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients

    Blood, Vol. 127, Núm. 25, pp. 3165-3174

  3. Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: A new model to understand chemoresistance

    Blood, Vol. 127, Núm. 15, pp. 1896-1906

  4. Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM

    Blood, Vol. 127, Núm. 4, pp. 420-425

2015

  1. Bendamustine, bortezomib and prednisone for the treatment of patients with newly diagnosed multiple myeloma: Results of a prospective phase 2 Spanish/PETHEMA trial

    Haematologica, Vol. 100, Núm. 8, pp. 1096-1102